Your browser is no longer supported. Please, upgrade your browser.
Settings
CANF [AMEX]
Can-Fite BioPharma Ltd.
Index- P/E- EPS (ttm)-1.20 Insider Own1.07% Shs Outstand17.19M Perf Week1.96%
Market Cap35.76M Forward P/E- EPS next Y-0.63 Insider Trans0.00% Shs Float16.53M Perf Month-4.59%
Income- PEG- EPS next Q-0.16 Inst Own11.25% Short Float3.28% Perf Quarter-22.96%
Sales0.76M P/S46.87 EPS this Y61.80% Inst Trans- Short Ratio0.15 Perf Half Y1.51%
Book/sh0.39 P/B5.33 EPS next Y50.00% ROA- Target Price- Perf Year16.85%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.51 - 4.39 Perf YTD16.85%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-52.62% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low37.75% ATR0.10
Employees8 Current Ratio- Sales Q/Q-21.90% Oper. Margin- RSI (14)45.34 Volatility5.49% 5.07%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.03 Prev Close1.97
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume3.71M Price2.08
Recom2.00 SMA20-2.05% SMA50-6.93% SMA2001.73% Volume113,876 Change5.58%
Aug-11-17Initiated Maxim Group Buy $7
Oct-19-16Resumed ROTH Capital Buy
Aug-29-16Resumed Rodman & Renshaw Buy $6
Nov-30-15Reiterated H.C. Wainwright Buy $4 → $6
Mar-31-15Reiterated H.C. Wainwright Buy $7 → $3
Mar-30-15Downgrade ROTH Capital Buy → Neutral $20 → $2.40
Dec-29-14Reiterated ROTH Capital Buy $28 → $20
Nov-18-14Initiated H.C. Wainwright Buy $7
May-12-21 09:30AM  
May-06-21 07:00AM  
Apr-29-21 07:00AM  
Apr-22-21 08:07AM  
07:20AM  
Apr-20-21 11:18AM  
07:00AM  
Apr-05-21 11:46AM  
07:00AM  
Mar-30-21 08:00AM  
Mar-25-21 08:29AM  
Mar-19-21 07:00AM  
Mar-18-21 07:15AM  
Mar-16-21 09:38AM  
08:17AM  
07:58AM  
07:00AM  
Mar-05-21 07:00AM  
Feb-26-21 08:58AM  
Feb-22-21 08:21AM  
07:10AM  
Feb-01-21 07:00AM  
Jan-28-21 07:00AM  
Jan-19-21 01:26PM  
Jan-08-21 07:00AM  
Jan-04-21 07:00AM  
Dec-22-20 06:00AM  
Dec-15-20 07:00AM  
Dec-14-20 07:00AM  
Dec-03-20 07:00AM  
Nov-30-20 07:00AM  
Nov-24-20 07:00AM  
Nov-23-20 07:00AM  
Nov-16-20 07:00AM  
Nov-09-20 07:00AM  
Oct-15-20 08:03AM  
Oct-13-20 07:00AM  
Oct-06-20 07:30AM  
Sep-30-20 07:00AM  
Sep-22-20 07:00AM  
Sep-08-20 07:00AM  
Aug-31-20 05:00PM  
07:00AM  
Aug-27-20 07:00AM  
Aug-26-20 07:00AM  
Aug-25-20 08:09AM  
Aug-20-20 07:00AM  
Aug-05-20 09:00AM  
Jul-27-20 07:00AM  
Jul-20-20 07:00AM  
Jul-15-20 07:00AM  
Jul-06-20 08:00AM  
Jun-30-20 07:00AM  
Jun-10-20 08:00AM  
Jun-09-20 07:00AM  
Jun-08-20 07:25AM  
Jun-04-20 07:14AM  
Jun-03-20 07:00AM  
Jun-01-20 07:00AM  
06:30AM  
May-28-20 07:00AM  
May-21-20 07:00AM  
May-18-20 07:00AM  
May-15-20 07:00AM  
Apr-28-20 11:04AM  
Apr-27-20 09:48AM  
Apr-14-20 07:00AM  
Apr-13-20 09:54AM  
06:30AM  
Apr-07-20 09:00AM  
Mar-30-20 07:00AM  
Mar-27-20 07:00AM  
Mar-23-20 07:45AM  
Mar-18-20 07:00AM  
Mar-16-20 07:00AM  
Mar-13-20 10:53AM  
08:13AM  
07:54AM  
07:00AM  
Mar-11-20 11:06AM  
07:30AM  
Mar-06-20 10:45AM  
Mar-05-20 08:05AM  
07:00AM  
Mar-03-20 07:00AM  
Feb-27-20 06:00AM  
Feb-24-20 07:00AM  
Feb-18-20 07:10AM  
Feb-13-20 07:00AM  
Feb-10-20 02:48PM  
Feb-03-20 07:30AM  
Jan-16-20 07:00AM  
Jan-09-20 09:10AM  
Jan-07-20 08:20AM  
Jan-06-20 10:06AM  
07:00AM  
Jan-03-20 07:00AM  
Dec-30-19 09:17AM  
Dec-27-19 10:02AM  
Dec-26-19 07:00AM  
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah-Tikva, Israel.